{
    "root": "30b39516-075b-29f9-e063-6294a90ac30c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Estratest FS",
    "value": "20250310",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "ESTROGENS, ESTERIFIED",
            "code": "3ASP8Q3768"
        },
        {
            "name": "METHYLTESTOSTERONE",
            "code": "V9EFU16ZIF",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27436"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        }
    ],
    "indications": {
        "text": "estratest h.s . estratest f.s . indicated treatment : moderate severe vasomotor symptoms associated menopause patients improved estrogens alone . ( evidence estrogens effective nervous symptoms depression without associated vasomotor symptoms , used treat conditions . ) estratest h.s . estratest f.s . shown effective purpose pregnancy may cause severe harm fetus ( boxed warning ) .",
        "doid_entities": [
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "1. given cyclically short-term : treatment moderate severe vasomotor symptoms associated menopause patients improved estrogen alone . lowest dose control symptoms chosen medication discontinued promptly possible . cyclic ( e.g . , three weeks one week ) . attempts discontinue taper medication made three- six month intervals . 2. usual range : 1 tablet estratest f.s . 1 2 tablets estratest h.s . daily recommended physician . treated patients intact uterus monitored closely signs endometrial cancer appropriate diagnostic measures taken rule malignancy event persistent recurring abnormal vaginal bleeding .",
        "doid_entities": [
            {
                "text": "endometrial cancer (DOID:1380)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1380"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "estratest f.s . bottles 100. estratest f.s . light green , oval-shaped , biconvex tablet debossed `` 640 `` one side scripted `` e `` side . contains : 1.25 mg esterified estrogens , usp 2.5 mg methyltestosterone , usp . estratest h.s . bottles 100. estratest h.s . dark green , oval-shaped , biconvex tablet debossed `` 639 `` one side scripted `` e `` side . contains : 0.625 mg esterified estrogens , usp 1.25 mg methyltestosterone , usp . store 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) ; excursions permitted 15\u00b0-30\u00b0c ( 59\u00b0-86\u00b0f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "estrogens used women following conditions : 1. known suspected cancer breast except appropriately selected patients treated metastatic disease . 2. known suspected estrogen-dependent neoplasia . 3. known suspected pregnancy ( boxed warning ) . 4. undiagnosed abnormal genital bleeding . 5. active thrombophlebitis thromboembolic disorders . 6. past history thrombophlebitis , thrombosis , thromboembolic disorders associated previous estrogen ( except treatment breast malignancy ) . methyltestosterone used : 1. presence severe liver damage . 2. pregnancy breast-feeding mothers possibility masculinization female fetus breast-fed infant .",
    "indications_original": "ESTRATEST H.S. AND ESTRATEST F.S. are indicated in the treatment of:  Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.)\n                  \n                  ESTRATEST H.S. AND ESTRATEST F.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING).",
    "contraindications_original": "1.\n  \n                        Given cyclically for short-term use only:\n                     \n                  \n                  For treatment of moderate to severe vasomotor symptoms associated with the menopause in patients not improved by estrogen alone.\n                  The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible.\n                  Administration should be cyclic (e.g., three weeks on and one week off). Attempts to discontinue or taper medication should be made at three- to six month intervals.\n                  \n                     \n                        2. Usual Dosage Range:\n                     \n                  \n                  1 tablet of ESTRATEST F.S. or 1 to 2 tablets of ESTRATEST H.S. daily as recommended by the physician.\n                  \n                     \nTreated patients with an intact uterus should be monitored closely for signs of endometrial cancer and appropriate diagnostic measures should be taken to rule out malignancy in the event of persistent or recurring abnormal vaginal bleeding.",
    "warningsAndPrecautions_original": "ESTRATEST F.S. in bottles of 100.\n  \nESTRATEST F.S. light green, oval-shaped, biconvex tablet debossed with \"640\" on one side and scripted \"E\" on other side.\n  \nContains: 1.25 mg of Esterified Estrogens, USP and 2.5 mg of Methyltestosterone, USP.\n  \nESTRATEST H.S. in bottles of 100.\n  \nESTRATEST H.S. dark green, oval-shaped, biconvex tablet debossed with \"639\" on one side and scripted \"E\" on other side.\n  \nContains: 0.625 mg of Esterified Estrogens, USP and 1.25 mg of Methyltestosterone, USP.\n  \nStore at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F); excursions permitted to 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F). [See USP Controlled Room\n  \nTemperature.]",
    "adverseReactions_original": "Estrogens should not be used in women with any of the following conditions:\n  \n1. Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic\n  \ndisease.\n  \n2. Known or suspected estrogen-dependent neoplasia.\n  \n3. Known or suspected pregnancy (See Boxed Warning).\n  \n4. Undiagnosed abnormal genital bleeding.\n  \n5. Active thrombophlebitis or thromboembolic disorders.\n  \n6. A past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use\n  \n(except when in treatment of breast malignancy).\n \n                  \n                     \nMethyltestosterone should not be used in:\n  \n1. The presence of severe liver damage.\n  \n2. Pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or\n  \nbreast-fed infant.",
    "drug": [
        {
            "name": "Estratest FS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ]
}